RCRI (Revised Cardiac Risk Index) Calculator

How to Use This Calculator

1. Select Yes/No for each of the 6 RCRI risk factors based on the patient's history and planned surgery type.
2. RCRI score, MACE risk percentage, and risk category display instantly.
3. Use the Preop Testing tab for ACC/AHA-based testing recommendations.
4. Use the Perioperative Management tab for beta-blocker and statin guidance.

Formula

Example

Frequently Asked Questions

• What is the RCRI and how was it derived? ▼
  The Revised Cardiac Risk Index (RCRI), also called the Lee Index or Lee Revised Cardiac Risk Index, is the most widely validated preoperative risk stratification tool for predicting major adverse cardiac events (MACE) in patients undergoing elective non-cardiac surgery. It was developed by Lee et al. at Brigham and Women's Hospital and published in Circulation in 1999. It was derived from a prospective cohort of 2,893 patients aged 50 or older undergoing major elective non-cardiac surgery and validated in a separate cohort of 1,422 patients. The six independent predictors identified were: high-risk surgery type (intraperitoneal, intrathoracic, or suprainguinal vascular procedures), history of ischemic heart disease (MI, abnormal stress test, angina, nitrate use, or pathological Q waves on EKG), history of congestive heart failure, history of cerebrovascular disease (stroke or transient ischemic attack), preoperative insulin therapy for diabetes, and preoperative serum creatinine greater than 2.0 mg/dL. Each factor scores 1 point; the total score ranges from 0 to 6. MACE includes MI, pulmonary edema, VF/VT, complete heart block, and cardiac death. The RCRI is endorsed as the primary perioperative cardiac risk tool by both the ACC/AHA and ESC guidelines for non-cardiac surgery.
• What are the four RCRI risk tiers and their MACE rates? ▼
  The Revised Cardiac Risk Index stratifies patients undergoing non-cardiac surgery into four perioperative cardiac risk tiers based on the total score. Very low risk (RCRI score 0): 0.4% MACE rate. Patients with no risk factors have an extremely low perioperative cardiac risk and can proceed to elective surgery without cardiac testing in most cases. Low risk (RCRI score 1): 1.0% MACE rate. One risk factor represents low but non-trivial cardiac risk. ACC/AHA guidelines consider perioperative cardiac risk less than 1% to be acceptable for elective non-cardiac surgery without additional testing. Moderate risk (RCRI score 2): 2.4% MACE rate. Two risk factors represent intermediate cardiac risk. ACC/AHA guidelines recommend considering the patient's functional capacity at this tier before deciding on further testing. High risk (RCRI score 3 or more): 5.4% MACE rate. Three or more risk factors represent substantially elevated perioperative cardiac risk. In these patients, the ACC/AHA guidelines recommend considering non-invasive cardiac testing before high-risk surgery if the results will change management. The absolute MACE rates in contemporary practice may differ from these original Lee et al. figures due to improvements in perioperative care, anesthesia, and post-operative monitoring.
• When is preoperative cardiac stress testing indicated based on RCRI? ▼
  Preoperative cardiac stress testing is not routinely recommended for most patients undergoing non-cardiac surgery — a principle emphasized in both ACC/AHA 2014 guidelines and ESC 2022 guidelines. The decision to obtain preoperative stress testing depends on three factors: the RCRI score (surgical and patient-related risk), the patient's functional capacity (METs), and whether the test result will actually change perioperative management. For patients with RCRI 0-1 (very low or low risk), stress testing is generally not recommended regardless of functional capacity. For patients with RCRI 2 or more (moderate or high risk) with adequate functional capacity of 4 METs or greater — able to walk up a flight of stairs, walk on level ground at 4 mph, or do moderate household work without limiting symptoms — stress testing provides little incremental information and is not recommended routinely. For patients with RCRI 2 or more with poor functional capacity (less than 4 METs) or unknown functional capacity, pharmacological stress testing (dobutamine stress echocardiography or nuclear perfusion) may be considered IF the results would change the surgical approach, medical management, or lead to coronary revascularization that would reduce perioperative risk. If the surgical plan would proceed regardless of the stress test result, the test should not be ordered — it only exposes the patient to cost, delay, and potential downstream invasive procedures without benefit.
• What is the role of perioperative beta-blockers in RCRI-guided management? ▼
  Perioperative beta-blocker management is one of the most nuanced and evidence-driven areas in preoperative cardiac care, and the RCRI plays a central role in guiding this decision. The clearest recommendation is for continuation of existing beta-blockers: patients already taking beta-blockers for ischemic heart disease, heart failure, or other indications must continue them perioperatively — abrupt discontinuation increases the risk of rebound tachycardia and myocardial ischemia (ACC/AHA Class I recommendation). Starting new perioperative beta-blockers without prior titration is explicitly contraindicated based on the POISE trial (PeriOperative ISchemic Evaluation), which showed that initiating high-dose metoprolol succinate within 4 hours of surgery significantly increased stroke risk and all-cause mortality despite reducing MACE and atrial fibrillation. For patients with RCRI 3 or higher who do not currently take beta-blockers, consideration of initiating beta-blocker therapy at least 1 week before surgery with careful heart rate titration (target HR 60-65 bpm on a low dose) is a Class IIb recommendation — reasonable in high-risk patients when adequate titration time is available before elective procedures. For patients with RCRI 1-2, routine beta-blocker initiation is not recommended and may cause harm (Class III).
• How does the RCRI compare to the ESC NSQIP risk calculator for perioperative risk? ▼
  The RCRI remains the most widely used preoperative cardiac risk score globally, but several alternative or complementary tools have been developed and validated. The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) Surgical Risk Calculator is a procedure-specific tool that incorporates over 20 variables including the type and complexity of the planned operation to estimate multiple postoperative complications, not just cardiac outcomes. It tends to be more granular for predicting 30-day MACE in specific surgical specialties. The ESC 2022 Non-Cardiac Surgery Guidelines continue to recommend the RCRI as the primary cardiac risk stratification tool but acknowledge its limitations: it was derived in an older population, does not account for emergency surgery urgency, and has a c-statistic of approximately 0.75 in most validation cohorts — reasonable but not excellent. The guidelines also emphasize that surgical risk is not captured by the RCRI alone — the planned procedure type (low-risk: cataract, endoscopy; intermediate-risk: intraabdominal; high-risk: major vascular) modifies the estimated MACE risk independently. In clinical practice, RCRI should be combined with surgical risk stratification, functional capacity assessment, and clinical judgment, with the ACC/AHA stepwise algorithm providing the most evidence-based structured approach to preoperative cardiac evaluation.

Related Calculators